Gubra Appoints Adam Lange as Head of Investor Relations
19 maj, 07:30
Gubra today announced the appointment of Adam Lange as the company’s new Head of Investor Relations, effective June 1, 2026.
Adam Lange joins Gubra with significant experience across investor relations, finance, and business development functions in pharmaceutical and biotech companies of different stages and sizes, including Novo Nordisk, Zealand Pharma, and UNION therapeutics, with exposure to obesity and metabolic disease, immunology, and inflammation. Most recently, he served as Head of Investor Relations at Zealand Pharma.
“We are very pleased to welcome Adam to Gubra,” said Kristian Borbos, Chief Financial Officer of Gubra. “Adam brings a strong track record within investor relations and broad experience from pharmaceutical and biotech companies in therapeutic areas of strategic importance to Gubra. His experience will be highly valuable as we continue to strengthen our position in the market and engage with the investment community around Gubra’s long-term strategy and growth opportunities.”
Adam Lange commented:
“I am excited to join Gubra at an important and dynamic stage of the company’s journey. Gubra has established a strong scientific platform validated by multiple partnerships and a unique business model around its Biotech unit, pre-clinical CRO services, and the newly launched Ventures arm. I look forward to working closely with management, investors, and analysts to communicate the company’s progress and long-term value creation potential.”
Contacts at Gubra
Media: Marianne Thomas (mho@gubra.dk, +45 2483 2663)
Investors: Kristian Borbos (kbo@gubra.dk, +45 3080 8035) and Emma Jappe Lange (ejl@gubra.dk, +45 5361 6755)
About Gubra
Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra’s activities are focused on the early stages of drug development and are organized in three main business units – Biotech, CRO, and Ventures. The business areas create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around $400 million) in 2025. See www.gubra.dk for more information.
Ämnen i artikeln
Gubra Appoints Adam Lange as Head of Investor Relations
19 maj, 07:30
Gubra today announced the appointment of Adam Lange as the company’s new Head of Investor Relations, effective June 1, 2026.
Adam Lange joins Gubra with significant experience across investor relations, finance, and business development functions in pharmaceutical and biotech companies of different stages and sizes, including Novo Nordisk, Zealand Pharma, and UNION therapeutics, with exposure to obesity and metabolic disease, immunology, and inflammation. Most recently, he served as Head of Investor Relations at Zealand Pharma.
“We are very pleased to welcome Adam to Gubra,” said Kristian Borbos, Chief Financial Officer of Gubra. “Adam brings a strong track record within investor relations and broad experience from pharmaceutical and biotech companies in therapeutic areas of strategic importance to Gubra. His experience will be highly valuable as we continue to strengthen our position in the market and engage with the investment community around Gubra’s long-term strategy and growth opportunities.”
Adam Lange commented:
“I am excited to join Gubra at an important and dynamic stage of the company’s journey. Gubra has established a strong scientific platform validated by multiple partnerships and a unique business model around its Biotech unit, pre-clinical CRO services, and the newly launched Ventures arm. I look forward to working closely with management, investors, and analysts to communicate the company’s progress and long-term value creation potential.”
Contacts at Gubra
Media: Marianne Thomas (mho@gubra.dk, +45 2483 2663)
Investors: Kristian Borbos (kbo@gubra.dk, +45 3080 8035) and Emma Jappe Lange (ejl@gubra.dk, +45 5361 6755)
About Gubra
Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra’s activities are focused on the early stages of drug development and are organized in three main business units – Biotech, CRO, and Ventures. The business areas create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around $400 million) in 2025. See www.gubra.dk for more information.
Ämnen i artikeln
Avanza-rapport
Ericsson
Rapporter i urval
Börser globalt
Aktieanalys
Avanza-rapport
Ericsson
Rapporter i urval
Börser globalt
Aktieanalys
Marknadsöversikt
1 DAG %
Senast
1 mån
